top of page

Our Clinical Trials

Lung Trials

AstraZeneca D516FC00001- ADAURA 2

​

A Phase III, Double-blind, Randomised, Placebo-Controlled, International
Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumor Resection (ADAURA2)

​

ClinicalTrials.gov ID: NCT05120349

​​

AstraZeneca D419ML00003 – TRITON

​

A Phase IIIb, Randomized, Multicenter, Open-label Study, to assess the
Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with PlatinumBased
Chemotherapy for FirstLine Treatment in Metastatic NonSmallCell Lung Cancer Patients with Non-Squamous
Histology who have Mutations and/or Comutations in STK11, KEAP1, or KRAS (TRITON)

​

ClinicalTrials.gov ID: NCT06008093

​

Merck V940-002

​

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study
of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

​​

ClinicalTrials.gov ID: NCT06077760

​

AstraZeneca D967SC00001 – DESTINY 04

An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the
Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or
Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

​

ClinicalTrials.gov ID: NCT05048797

​

SeaGen SGNB6A-002

​

​A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in
adult subjects with previously treated non-small cell lung cancer

​

ClinicalTrials.gov ID: NCT06012435

​

​

Leukemia Trials

Novartis CABL001AUS08

​

A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase – Chronic Myelogenous Leukemia (ASC2ESCALATE)

​

ClinicalTrials.gov ID: NCT05384587

​​

​

BeiGene BGB-11417-301​

​

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib(BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia

​

ClinicalTrials.gov ID: NCT06073821

​

​

​

Lymphoma Trials

Genentech ML 43389 (Morning Sun)

​

An Open-Label, Multicenter, Phase II Trial, Evaluating the Safety, Efficacy, and
Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients with Select B-Cell Malignancies

​

ClinicalTrials.gov ID: 

​

Genentech GO44145 (SkyGlo)

​

​A Phase III, multicenter, randomized, open-label study comparing the efficacy &
safety of Glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, & prednisone (POLA-R-CHP) vs POLA-R-CHP in previously untreated patients with Large B-Cell Lymphoma

​

ClinicalTrials.gov ID: NCT06047080

​

BMS CA073-1022 (GOLSEEK-2)​

​

​A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy & Safety of
Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma

​

ClinicalTrials.gov ID: NCT06425302

​

Genentech GO43643 (SUNMO)

​

A Randomized, Open-Label, Multicenter Phase 3 Study Evaluating Efficacy and
Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin in Comparison with Rituximab in Combination With Gemcitabine plus Oxaliplatin in Participants with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma

​

ClinicalTrials.gov ID: NCT05171647

​

LOXO Lilly BTK-200019

​

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)

​

ClinicalTrials.gov ID: NCT04662255

Breast Trials

Novartis CLEE011O12001

​

A Phase 3b Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a
wide Patient Population with ER+, HER2- Early Breast Cancer (Adjuvant WIDER)

​

ClinicalTrials.gov ID: NCT05827081

​

Genentech ML43171

​

A Phase 3, Open-label, Multicenter Study Evaluating the Efficacy and Safety of Giradestrant Plus Everolimus Compared with Exemestane plus Everolimus in Patients with Estrogen Receptor-Positive, HER2 Negative, Locally Advanced or Metastatic Breast Cancer

​​

ClinicalTrials.gov ID: NCT05306340

​

AstraZeneca D926XC00001

​

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With
or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)

​

ClinicalTrials.gov ID: NCT05629585

​

​

Prostate Trials

Xencor XmAb20717-04

​

A Phase 2 Multiple Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety,
Tolerability, & Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration Resistant Prostate Cancer

​

ClinicalTrials.gov ID: NCT05005728

​

Hengrui SHR3162-III-305

​

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of
Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

​

ClinicalTrials.gov ID: NCT04691804

​

​​​

​

​

​

bottom of page